Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Roquefort Investments PLC ( (GB:ROQ) ) just unveiled an update.
Roquefort Therapeutics PLC announced that Dr. Darrin Disley, the Interim Managing Director, has purchased 5,000,000 ordinary shares of the company at an average price of 1.70 pence per share, amounting to a total consideration of £85,000. This acquisition increases Dr. Disley’s total shareholding to 7,024,196 shares, representing 4.46% of the company’s issued capital. This move could signal confidence in the company’s strategic direction and its ongoing efforts to acquire rights to a novel cancer treatment drug, potentially impacting its market positioning and stakeholder interests.
More about Roquefort Investments PLC
Roquefort Therapeutics PLC is a biotech company listed on the Main Market of the London Stock Exchange. The company is focused on acquiring exclusive license rights to AO-252, a novel drug targeting the TACC3 protein for cancer treatment, through a proposed transaction with A2A Pharmaceuticals, Inc. and Coiled Therapeutics, Inc.
Average Trading Volume: 2,186,541
Technical Sentiment Signal: Sell
Current Market Cap: £2.99M
For detailed information about ROQ stock, go to TipRanks’ Stock Analysis page.